Motilal Oswal Private Equity invests RS 194.4 crore in Pathkind Diagnostics

By Sumit Blogs -

India Business Excellence Fund – IV, a fund managed by Private Equity (MOPE) on Friday said it has agreed to make a primary investment of upto Rs 194.4 crore in Mankind Pharma-backed Pathkind Diagnostics – a pathology chain with operations across 23 states in India.

Pathkind will use the proceeds for expansion in South India.

Established in 2016, Pathkind is one of the fastest growing diagnostics services chains in India with a network of over 75 labs of which 13 are NABL accredited, 2,000 exclusive collection centers and over 5,000 business-to-business clients, across 23 states.

The lab chain is promoted by diagnostic industry veteran Sanjeev Vashishta and the promoters of Mankind Pharma.

Pathkind operates in the pathology and wellness segment and offers a portfolio of over 4,000 tests

“We believe that the diagnostics industry in India is poised to grow to $30 billion over the next 8-10 years, driven primarily by increasing penetration and shift towards organized diagnostics chains,” said Vishal Tulsyan, MD and CEO of MOPE.

“Pathkind, with its focus on providing quality testing, widespread network, extensive doctor coverage, strong management team and parentage and with our investment, is well poised to be a leading diagnostics franchise in India,” Tulsyan said.

This is MOPE’s second investment in the healthcare industry, the first one being in a medical equipment company.

“Settin up labs run by qualified pathologist doctors, skilled technicians and scientists in every nook and corner of the country using state of the art technology and automated platforms, such that the patients don’t have to travel long distances for their diagnostics requirements, is our top priority. The funding will be utilized judiciously to further build on the diagnostics capabilities and capacities, educating the masses about the virtues of early diagnosis and to augment ourservices using digitization, AI, ML tools apart from other things,” said Sanjeev Vashishta, MD and CEO of Pathkind.

“This primary investment coming in Pathkind will be utilized to further develop our IT infrastructure, digital marketing and expansion into southern India making us a Pan-India player within 6 months,” said Eklavya Juneja, director and promoter Pathkind Diagnostics.

Khaitan & Co, Wadia Ghandy & Co, and Ray Legal were the legal advisors to the transaction.

MOPE is managing both private equity and real estate funds and cumulatively manages around $ 2 billion between the two asset classes. The private equity vertical focuses on providing growth capital to mid-market companies across its preferred sectors of consumer, financial services, life sciences and niche manufacturing, typically in the range of Rs 200- 500 crore. The private equity vertical has, in the last 15 years, made over 35 investments and has completely exited 14 investments.

Credits – Source – https://ift.tt/fWVuwIi

The post Motilal Oswal Private Equity invests RS 194.4 crore in Pathkind Diagnostics appeared first on Stay in Gurgaon.

Comments

Post a Comment

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

By Sumit Blogs -
Image
By Economic Times – Flat sale of flu drugs hints at no unusual rise in infections Industry executives and chemists said the April sales data showed a month-on-month decline of 30-40%. But even though the lockdown is seen to be impacting sales of most drugs, the pattern for medicines for infections and flus is no different.Last Updated: Apr 30, 2020, 11.23 AM ISTAgenciesExperts said the decline in sales was primarily because of the lockdown and other restrictions which forced people to stay indoors. (This story originally appeared in on Apr 30, 2020)NEW DELHI: Sales of anti-infectives (antibiotics and antivirals), respiratory drugs, painkillers and analgesics — some key medicines used for influenza-like illnesses — have remained mostly unchanged in last three months (January to March), partly explained by the lockdown but also indicating no unusual rise in flu-type infections that might point to a wider and undetected spread of Covid-19. Sales of most medicines, including this set of
Read more

10YearsForSimha: Reasons behind film’s success

By Sumit Blogs -
Image
By Times of India – 10YearsForSimha: Reasons behind film’s success TIMESOFINDIA.COM | Last updated on – Apr 30, 2020, 06:00 ISTclose01/6Take a look at the reasons behind the film’s successDirected by Boyapati Srinu, the 2010 film Simha was a game-changer among Tollywood films that was lauded, not only for Nandamuri Balakrishna’s intense performance in the dual role but also the gripping narration of the filmmaker. Balayya and Nayanthara were seen on the big screen for the first time ever in the film. The action drama made a special place in the hearts of the audience because of its simple storytelling, superhit songs and unbeatable chemistry between the lead pair. The movie has completed a decade, but the essence is as fresh as it was back then. As the film clocks 10 years of its release, find out the reasons behind the massive success of the Balakrishna starrer.readmore02/6​Boyapati Srinu’s gripping narrationBefore Simha, Boyapati Srinu had delivered Bhadra (2005) and Tulasi (2007),
Read more

Hrithik-Saif’s Vikram Vedha hits a roadblock

By Sumit Blogs -
Image
The stage was about to be set for Hrithik Roshan and Saif Ali Khan’s ‘Vikram Vedha’ in Mumbai’s Film City. The material had reached. The artisans had been hired. But the lights have now been dimmed. Madhavan and Vijay Sethupathi’s hit movie Vikram Vedha’s Hindi remake will not go on floors by mid-July as per the original plan. The new delta virus of COVID has sent shudders down many spines and many films which were being laid out on an expansive scale have been either held back or shifted their shoots abroad. The first schedule of this Hrithik-Saif movie will now be shot abroad. A source says, “The Mumbai schedule will be done but later.” Adds the source, “It’s a call that was taken yesterday. It wasn’t an easy call to take, no doubt, but the fact that it’s going to be a costly set made the makers take the safer route rather than be sorry later.” When contacted, General Secretary of FWICE (Federation of Western India Cine Employees), Ashok Dubey, confirmed that the makers of ‘V
Read more